Related Experiment Video

Updated: Jan 19, 2026

Integration of Bioinformatics Approaches and Experimental Validations to Understand the Role of Notch Signaling in Ovarian Cancer
09:08

Integration of Bioinformatics Approaches and Experimental Validations to Understand the Role of Notch Signaling in Ovarian Cancer

Published on: January 12, 2020

7.2K

Multi-omics profiling reveals key signaling pathways in ovarian cancer controlled by STAT3

Tiangong Lu1, Armand Bankhead2,3, Mats Ljungman4

  • 1Department of Medicinal Chemistry, College of Pharmacy, Rogel Cancer Center, University of Michigan, Ann Arbor, MI 48109-2800, USA.

Theranostics
|September 20, 2019
PubMed

Insights

STAT3 (Signal Transducer and Activator of Transcription 3) deletion inhibits ovarian cancer cell growth and migration. This study reveals STAT3

Area of Science:

  • Oncology
  • Molecular Biology
  • Genetics

Background:

  • Signal Transducer and Activator of Transcription 3 (STAT3) signaling is implicated in tumor progression, metastasis, and chemoresistance.
  • The exact molecular mechanisms of STAT3's role in ovarian cancer remain incompletely understood.

Purpose of the Study:

  • To investigate the functional and molecular consequences of STAT3 deletion in ovarian cancer.
  • To elucidate the role of STAT3 in ovarian cancer cell proliferation, migration, and tumor growth.

Main Methods:

  • Generated STAT3 knockout (KO) ovarian cancer cell lines.
  • Assessed effects of STAT3 KO on cell proliferation, migration, and spheroid formation in vitro.
  • Evaluated in vivo tumor growth using xenograft models.
  • Performed multi-omic genome-wide profiling (Bru-Seq, RNA-Seq, MS Proteomics) to identify expression signatures.

Main Results:

  • STAT3 deletion significantly blocked ovarian cancer cell proliferation and migration in vitro.
  • STAT3 KO suppressed tumor growth in vivo.
  • STAT3 deletion transcriptionally downregulated genes involved in epithelial-mesenchymal transition (EMT), cell cycle progression, and E2F signaling.
  • STAT3 KO altered stemness markers and modulated the expression of other STAT family members.

Conclusions:

  • STAT3 deletion profoundly impacts key molecular pathways driving ovarian cancer.
  • This study provides comprehensive molecular insights into STAT3's function in ovarian cancer.
  • STAT3 represents a promising therapeutic target for ovarian cancer treatment.
Keywords:
CRISPR-Cas9Multi-omic genome-wide analysisOvarian cancerSTAT3STAT3 knockout

More Related Videos

Author Spotlight: Unveiling the Role of TMOD3 in Platinum Resistance and Immune Infiltration in Ovarian Cancer09:40

Author Spotlight: Unveiling the Role of TMOD3 in Platinum Resistance and Immune Infiltration in Ovarian Cancer

Published on: August 2, 2024

3.2K
Evaluating the Angiogenetic Properties of Ovarian Cancer Stem-Like Cells using the Three-Dimensional Co-Culture System, NICO-107:59

Evaluating the Angiogenetic Properties of Ovarian Cancer Stem-Like Cells using the Three-Dimensional Co-Culture System, NICO-1

Published on: December 5, 2020

3.0K

Related Concept Videos

PI3K/mTOR/AKT Signaling Pathway01:22

PI3K/mTOR/AKT Signaling Pathway

The mammalian target of rapamycin  (mTOR) is a serine/threonine kinase that regulates growth, proliferation, and cell survival in response to hormones, growth factors, or nutrient availability. This kinase exists in two structurally and functionally distinct forms: mTOR complex 1  (mTORC1) and mTOR complex 2  (mTORC2). The first form (mTORC1) is composed of a rapamycin-sensitive Raptor and proline-rich Akt substrate, PRAS40. In contrast,  mTORC2 consists of a...
5.4K
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
4.6K
Interactions Between Signaling Pathways01:19

Interactions Between Signaling Pathways

Signaling cascades usually lack linearity. Multiple pathways interact and regulate one another, allowing cells to integrate and respond to diverse environmental stimuli.
Convergence and divergence, and cross-talk between signaling pathways
Two distinct signaling pathways can converge on a single functional unit, which may either be a single protein or a complex of proteins. The response is either functionally distinct or synergistic between the two pathways but different from the response...
7.2K
Cancer-Critical Genes II: Tumor Suppressor Genes01:05

Cancer-Critical Genes II: Tumor Suppressor Genes

Genes usually encode proteins necessary for the proper functioning of a healthy cell. Mutations can often cause changes to the gene expression pattern, thereby altering the phenotype.
When the function of certain critical genes, especially those involved in cell cycle regulation and cell growth signaling cascades, gets disrupted, it upsets the cell cycle progression. Such cells with unchecked cell cycles start proliferating uncontrollably and eventually develop into tumors.
Such genes that act...
9.4K
The JAK-STAT Signaling Pathway01:20

The JAK-STAT Signaling Pathway

Several cytokine receptors have tightly bound Janus kinase or JAK proteins attached at their cytosolic tail. Small signaling molecules such as cytokines, growth hormones, or prolactins bind to the cytokine receptors and initiate their dimerization. The dimerization brings the cytosolic JAKs together that trans-phosphorylate and activates each other. The activated JAKs now phosphorylate cytosolic tails of the cytokine receptors, which serve as binding sites for adaptor proteins such as  SH2...
12.2K
Tumor Progression02:07

Tumor Progression

Tumor progression is a phenomenon where the pre-formed tumor acquires successive mutations to become clinically more aggressive and malignant. In the 1950s, Foulds first described the stepwise progression of cancer cells through successive stages.
Colon cancer is one of the best-documented examples of tumor progression. Early mutation in the APC gene in colon cells causes a small growth on the colon wall called a polyp. With time, this polyp grows into a benign, pre-cancerous tumor. Further...
7.2K